Trump announces all states join drug pricing plan

All 50 states will participate in the Medicaid GENEROUS model, which ties U.S. drug prices to the lowest prices paid in other wealthy countries.

White House claims $529 billion in savings

The Trump administration estimates the deals with pharmaceutical companies will save Medicaid $529 billion over the next 10 years by lowering U.S. drug prices.

Details of deals remain secret

Few details of the agreements between the Trump administration and pharmaceutical companies have been made public, making it impossible to independently verify the savings claims.

“No one knows what is in these deals.”

Experts demand transparency for Congress

Policy experts say the lack of public information creates a barrier to legislative action and makes it unclear what Congress would actually codify into law.

“He is saying Congress should codify all of his MFN arrangements. But it's kind of unreasonable because it's not clear what Congress would actually do.”

Concerns about deal longevity

Experts worry that price cuts may not survive beyond the Trump administration and could revert once a new administration takes office.

Millions still lack access to lower prices

While Medicaid patients benefit, millions of Americans with private insurance through employers or the individual market remain unable to access the lower drug prices.

“meaningful progress, but that progress remains incomplete”